Irinotecan-based therapy may benefit colon cancer patients with the CpG island methylator phenotype, which is present in approximately 10 percent to 20 percent of colorectal cancer cases.
“Our results serve as an example that the molecular characterization of individual tumors may help to determine the most appropriate treatment for patients with colon cancer,” said lead study author Stacey Shiovitz, MD, of the University of Washington in Seattle.
More articles on gastroenterology:
Are surveillance colonoscopy practices due for an update?
5 things to know about colonoscopy payment: AGA bundle vs. Medicare model
What is the optimal bowel preparation for colonoscopy?
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.